Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349465 · ClinicalTrials.gov registry record · Phase 3
3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection
A Phase 3 study, sponsored by Janssen R&D Ireland.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT01349465 is a Phase 3 study that has completed, run by Janssen R&D Ireland. The registered enrollment target is 249 participants.
The verdict
NCT01349465, a Phase 3 study, has completed, sponsored by Janssen R&D Ireland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate durability of SVR in chronic HCV patients who achieved SVR in the previous study with TMC435-containing regimen and time for resistance associated mutations to return to baseline in chronic HCV patients who did not achieve SVR in the previous study with TMC435-containing regimen.
Interventions
- DRUG No treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2011-07-04 |
| Est. Completion | 2016-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349465
The ClinicalTrials.gov registry entry for NCT01349465 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen R&D Ireland, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No treatment is the first listed.
NCT01349465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349465 about?
NCT01349465 is a clinical study titled "3-year Follow-up Study in Patients Previously Treated With TMC435-Containing Regimen for the Treatment of Hepatitis C Virus Infection". The purpose of this study is to investigate durability of SVR in chronic HCV patients who achieved SVR in the previous study with TMC435-containing regimen and time for resistance associated mutations to return to baseline in chronic HCV patients who did not achieve SVR in the previous study with TM...
What is the current status of trial NCT01349465?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2011-07-04. Estimated completion is 2016-01-05.
What interventions are being tested in trial NCT01349465?
The interventions under investigation include: No treatment (DRUG).
Who is sponsoring clinical trial NCT01349465?
This trial is sponsored by Janssen R&D Ireland, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.